SpringWorks Therapeutics, Inc.

NasdaqGS:SWTX Stock Report

Market Cap: US$2.3b

SpringWorks Therapeutics Valuation

Is SWTX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SWTX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: SWTX ($30.94) is trading below our estimate of fair value ($117.97)

Significantly Below Fair Value: SWTX is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for SWTX?

Other financial metrics that can be useful for relative valuation.

SWTX key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue20.4x
Enterprise Value/EBITDA-5.5x
PEG Ration/a

Price to Sales Ratio vs Peers

How does SWTX's PS Ratio compare to its peers?

The above table shows the PS ratio for SWTX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average7.5x
CPRX Catalyst Pharmaceuticals
5.9x13.3%US$2.6b
MNKD MannKind
7.8x14.0%US$2.0b
BCRX BioCryst Pharmaceuticals
3.7x15.1%US$1.7b
DCPH Deciphera Pharmaceuticals
12.7x23.6%US$2.2b
SWTX SpringWorks Therapeutics
26.7x43.5%US$2.3b

Price-To-Sales vs Peers: SWTX is expensive based on its Price-To-Sales Ratio (26.7x) compared to the peer average (7.5x).


Price to Earnings Ratio vs Industry

How does SWTX's PE Ratio compare vs other companies in the US Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a27.1%
n/an/an/a
No. of CompaniesPS048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a27.1%
n/an/an/a
No more companies

Price-To-Sales vs Industry: SWTX is expensive based on its Price-To-Sales Ratio (26.7x) compared to the US Biotechs industry average (12.6x).


Price to Sales Ratio vs Fair Ratio

What is SWTX's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SWTX PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio26.7x
Fair PS Ratio19x

Price-To-Sales vs Fair Ratio: SWTX is expensive based on its Price-To-Sales Ratio (26.7x) compared to the estimated Fair Price-To-Sales Ratio (19x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst SWTX forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$30.94
US$68.25
+120.6%
11.4%US$80.00US$58.00n/a8
Oct ’25US$32.22
US$68.13
+111.4%
11.6%US$80.00US$58.00n/a8
Sep ’25US$41.71
US$67.63
+62.1%
11.9%US$80.00US$58.00n/a8
Aug ’25US$35.26
US$66.70
+89.2%
10.8%US$80.00US$58.00n/a9
Jul ’25US$38.53
US$65.92
+71.1%
9.9%US$75.00US$58.00n/a9
Jun ’25US$41.46
US$67.36
+62.5%
10.9%US$77.00US$58.00n/a9
May ’25US$46.84
US$67.28
+43.6%
12.3%US$80.00US$55.00n/a8
Apr ’25US$47.62
US$67.78
+42.3%
11.2%US$80.00US$58.00n/a8
Mar ’25US$51.01
US$67.53
+32.4%
10.9%US$80.00US$58.00n/a8
Feb ’25US$44.53
US$57.17
+28.4%
20.8%US$74.00US$45.00n/a6
Jan ’25US$36.50
US$54.83
+50.2%
21.4%US$73.00US$41.00n/a6
Dec ’24US$31.90
US$54.83
+71.9%
21.4%US$73.00US$41.00n/a6
Nov ’24US$23.91
US$50.17
+109.8%
16.5%US$66.00US$41.00US$30.626
Oct ’24US$23.12
US$50.17
+117.0%
16.5%US$66.00US$41.00US$32.226
Sep ’24US$30.33
US$50.17
+65.4%
16.5%US$66.00US$41.00US$41.716
Aug ’24US$29.85
US$57.00
+91.0%
38.6%US$105.00US$41.00US$35.266
Jul ’24US$26.22
US$56.00
+113.6%
40.2%US$105.00US$41.00US$38.536
Jun ’24US$27.69
US$56.00
+102.2%
40.2%US$105.00US$41.00US$41.466
May ’24US$24.01
US$56.33
+134.6%
39.6%US$105.00US$41.00US$46.846
Apr ’24US$25.74
US$58.67
+127.9%
36.3%US$105.00US$45.00US$47.626
Mar ’24US$30.61
US$57.00
+86.2%
33.7%US$99.00US$45.00US$51.016
Feb ’24US$31.88
US$65.33
+104.9%
40.0%US$105.00US$45.00US$44.536
Jan ’24US$26.01
US$64.50
+148.0%
41.6%US$105.00US$40.00US$36.506
Dec ’23US$23.67
US$64.50
+172.5%
41.6%US$105.00US$40.00US$31.906
Nov ’23US$24.26
US$78.20
+222.3%
32.3%US$105.00US$44.00US$23.915

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.


Discover undervalued companies